To date, ddPCR has been used to detect MRD in AML via testing for NPM1 mutation, DNMT3A, IDH1/2, and BCR-ABL fusion, relatively uncommon targets in acute leukemia (21–25). Here, BCR is linked to acute myeloid leukemia.